About 3-mercaptopyruvate sulfurtransferase
3-mercaptopyruvate sulfurtransferase (MPST) is a protein
from Homo sapiens identified by UniProt accession
P25325, 297 residues long.
MolForge cross-references it against 0 known binders and
68 disease associations.
Target properties
| Protein name | 3-mercaptopyruvate sulfurtransferase |
|---|
| UniProt accession | P25325 |
|---|
| Gene | MPST |
|---|
| Organism | Homo sapiens |
|---|
| Length | 297 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (68)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.26
- mean corpuscular hemoglobin · score 0.21
- Red cell distribution width · score 0.20
- protein measurement · score 0.18
- eye colour measurement · score 0.18
- mean corpuscular hemoglobin concentration · score 0.09
- non-alcoholic fatty liver disease · score 0.08
- colitis · score 0.08
- inflammatory bowel disease · score 0.06
- Male infertility with spermatogenesis disorder due to single gene mutation · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P25325-F1 | alphafold | PREDICTED | 95.60 | — |
Amino-acid sequence (297 residues)
MASPQLCRAL VSAQWVAEAL RAPRAGQPLQ LLDASWYLPK LGRDARREFE ERHIPGAAFF DIDQCSDRTS PYDHMLPGAE HFAEYAGRLG VGAATHVVIY DASDQGLYSA PRVWWMFRAF GHHAVSLLDG GLRHWLRQNL PLSSGKSQPA PAEFRAQLDP AFIKTYEDIK ENLESRRFQV VDSRATGRFR GTEPEPRDGI EPGHIPGTVN IPFTDFLSQE GLEKSPEEIR HLFQEKKVDL SKPLVATCGS GVTACHVALG AYLCGKPDVP IYDGSWVEWY MRARPEDVIS EGRGKTH
Explore 3-mercaptopyruvate sulfurtransferase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets